ACBM Remains Pre-Revenue, Eyes Capital for Biomedical Future

TL;DR

**ACBM is a speculative bet on future biomedical breakthroughs, with zero revenue and high capital risk; avoid until commercialization is clear.**

AI Summary

ACRO BIOMEDICAL CO., LTD. (ACBM) reported no revenue for the fiscal year ended December 31, 2024, consistent with the prior year, indicating a pre-revenue or non-operational status. The company's net income is not explicitly stated but implied to be negative given the lack of revenue and ongoing operational costs. Key business changes include the continued focus on its biomedical initiatives, though specific advancements or product developments are not detailed. A significant risk factor is the company's reliance on future capital raises, as evidenced by its authorized common stock of 100,000,000 shares and 60,042,000 shares outstanding as of December 31, 2024, with a par value of $0.001 per share. The strategic outlook involves securing additional funding and advancing its biomedical projects, but the filing lacks concrete milestones or timelines. The company also maintains a 'Two Thousand Twenty Equity Incentive Plan' to attract and retain talent, with 25,000,000 shares reserved for issuance.

Why It Matters

ACRO BIOMEDICAL's continued pre-revenue status signals high risk for investors, as the company relies entirely on future capital raises to fund its biomedical ambitions. This lack of operational revenue puts pressure on its ability to attract and retain employees, who may seek more stable opportunities. For customers, the absence of products or services means no immediate impact, but the long-term success of its biomedical projects could introduce new solutions to the market. In a competitive biomedical landscape, ACBM's lack of commercialization makes it a distant player, far behind established firms with revenue streams and proven products.

Risk Assessment

Risk Level: high — The risk level is high due to ACRO BIOMEDICAL CO., LTD.'s complete lack of revenue for the fiscal year ended December 31, 2024, indicating no operational income. The company's reliance on future capital raises, with 60,042,000 shares outstanding and 25,000,000 shares reserved for its equity incentive plan, highlights significant dilution risk and dependence on external funding for survival.

Analyst Insight

Investors should exercise extreme caution and avoid ACBM shares until the company demonstrates a clear path to revenue generation and provides specific details on its biomedical product development. This is a highly speculative investment suitable only for those with a high-risk tolerance and a long-term horizon, willing to bet on unproven technology.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue reported for fiscal year 2024, indicating pre-revenue status.)
• 60,042,000 — Common Shares Outstanding (Total shares outstanding as of December 31, 2024, indicating potential for dilution.)
• 100,000,000 — Authorized Common Shares (Maximum shares the company can issue, allowing for significant future capital raises.)
• $0.001 — Par Value per Share (Nominal value of each common stock share.)
• 25,000,000 — Shares Reserved for Incentive Plan (Shares allocated for the Two Thousand Twenty Equity Incentive Plan, impacting future share count.)

Key Players & Entities

• ACRO BIOMEDICAL CO., LTD. (company) — filer of the 10-K
• Killer Waves Hawaii, Inc. (company) — former name of ACRO BIOMEDICAL CO., LTD.
• 07 Trade & Services (company) — organization name associated with the filer
• $0.001 (dollar_amount) — par value per share of common stock
• 100,000,000 (dollar_amount) — authorized shares of common stock
• 60,042,000 (dollar_amount) — shares of common stock outstanding as of December 31, 2024
• 25,000,000 (dollar_amount) — shares reserved for the Two Thousand Twenty Equity Incentive Plan
• SEC (regulator) — recipient of the 10-K filing
• Bloomberg (company) — publisher of this analysis

FAQ

Risk Factors

• Reliance on Future Capital Raises [high — financial]: The company has no reported revenue and is likely incurring operational costs, necessitating continuous funding. As of December 31, 2024, ACBM has 60,042,000 common shares outstanding out of 100,000,000 authorized shares, indicating significant capacity for future share issuance to raise capital.
• Pre-Revenue Status and Lack of Product Development Detail [high — operational]: ACBM reported no revenue for fiscal year 2024, mirroring the previous year. The company's focus remains on biomedical initiatives, but the filing lacks specific details on advancements, product development timelines, or concrete milestones, creating uncertainty about future revenue generation.
• Potential for Shareholder Dilution [medium — financial]: With 100,000,000 authorized common shares and 60,042,000 shares outstanding as of December 31, 2024, the company has substantial room to issue new shares. Furthermore, 25,000,000 shares are reserved under the 'Two Thousand Twenty Equity Incentive Plan', increasing the potential for future dilution.

Industry Context

ACRO BIOMEDICAL CO., LTD. operates within the biomedical sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The industry is competitive, with established players and numerous startups vying for funding and market share. Trends include advancements in biotechnology, personalized medicine, and digital health solutions.

Regulatory Implications

As a biomedical company, ACBM is subject to stringent regulations from bodies like the FDA (in the US) or equivalent international agencies. Compliance with these regulations is critical for product approval and market access, and failure to comply can result in significant delays, fines, or product recalls.

What Investors Should Do

1. Monitor Capital Raise Activities
2. Scrutinize Biomedical Project Updates
3. Assess Dilution Risk

Key Dates

• 2024-12-31: Fiscal Year End — Marks the end of the reporting period for which financial results are presented, showing no revenue and a specific share count.
• 2025-07-24: 10-K Filing Date — Indicates the date the annual report was officially submitted to the SEC, providing the latest available financial and operational information.

Glossary

Pre-revenue

A company that has not yet generated any sales or revenue from its products or services. (ACBM is in a pre-revenue stage, as evidenced by its $0 revenue for fiscal year 2024.)

Authorized Common Shares

The maximum number of common shares that a corporation is legally permitted to issue, as specified in its articles of incorporation. (ACBM has 100,000,000 authorized shares, indicating its capacity to raise significant capital through future stock offerings.)

Shares Outstanding

The total number of shares of a company's stock that are currently held by all its shareholders, including share blocks held by institutional investors and restricted shares of insiders. (ACBM had 60,042,000 shares outstanding as of December 31, 2024, a key figure for calculating market capitalization and potential dilution.)

Par Value

A nominal value assigned to a share of stock by the company that issues it. It is often a very small amount, like $0.001. (The $0.001 par value per share for ACBM's common stock is a standard accounting practice and does not reflect the market value.)

Equity Incentive Plan

A plan established by a company to grant stock options, restricted stock, or other equity-based awards to employees, directors, or consultants to incentivize performance and retention. (ACBM's 'Two Thousand Twenty Equity Incentive Plan' reserves 25,000,000 shares, which could impact future share counts and dilution.)

Year-Over-Year Comparison

The fiscal year 2024 10-K filing for ACRO BIOMEDICAL CO., LTD. shows no change in revenue, remaining at $0, consistent with the prior year's reporting. This indicates a continued pre-revenue status. No specific changes in net income, margins, or debt-to-equity ratios are detailed due to the lack of operational revenue. New risks related to the company's capital-raising strategy and the potential for dilution from its authorized and incentive-reserved shares are highlighted.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on July 24, 2025 regarding ACRO BIOMEDICAL CO., LTD. (ACBM).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR